key: cord-0273794-ovth8kwk authors: Liao, Guochao; Fan, Xingxing; Lau, Hungyan; Liu, Zhongqiu; Li, Chinyu; Xu, Zeping; Zhang, Yu; Qi, Xiaoxiao; Li, Dan; Zhu, Qing; Chen, Liqing; Zhou, Hua; Zhu, Sisi; Ke, Bixia; Pan, Hudan; Cong, Zhe; Li, Yongchao; Feng, Qian; Lv, Qi; Liu, Jiangning; Liang, Dan; Li, An’an; Hong, Wenshan; Li, Yebo; Bao, Linlin; Zhou, Feng; Gao, Hongbin; Liang, Shi; Huang, Bihong; Wu, Miaoli; Qin, Chuan; Ke, Changwen; Liu, Liang title: Single-shot rAAV5-based Vaccine Provides Long-term Protective Immunity against SARS-CoV-2 and Its Variants date: 2021-08-23 journal: bioRxiv DOI: 10.1101/2021.08.23.456471 sha: 63a65dadcc5436e528d9d13b07e0f5c8c77fffc5 doc_id: 273794 cord_uid: ovth8kwk The COVID-19 pandemic and the SARS-CoV-2 with its variants have posed unprecedented challenges worldwide. Existing vaccines have limited effectiveness against the SARS-CoV-2 variants. Therefore, novel vaccines to match current mutated viral lineages with long-term protective immunity are urgently in demand. In the current study, we for the first time designed a recombinant Adeno-Associated Virus 5 (rAAV5)-based vaccine named as rAAV-COVID-19 vaccine (Covacinplus) by using RBD-plus of spike protein with both the single-stranded and the self-complementary AAV5 delivering vectors (ssAAV5 and scAAAV5), which provides excellent protection from SARS-CoV-2 infection. A single dose vaccination induced the strong immune response against SARS-CoV-2. The induced neutralizing antibodies (NAs) titers were maintained at a high peak level of over 1:1024 even after more than one year of injection and accompanied with functional T-cells responses in mice. Importantly, both ssAAV- and scAAV-based RBD-plus vaccines exhibited high levels of serum NAs against current circulating variants including variants Alpha, Beta, Gamma and Delta. SARS-CoV-2 virus challenge test showed that ssAAV5-RBD-plus vaccine protected both young and old age mice from SARS-CoV-2 infection in the upper and the lower respiratory tracts. Moreover, whole genome sequencing demonstrated that AAV vector DNA sequences were not found in the genome of the vaccinated mice after one year vaccination, demonstrating excellent safety of the vaccine. Taken together, this study suggests that rAAV5-based vaccine is powerful against SARS-CoV-2 and its variants with long-term protective immunity and excellent safety, which has great potential for development into prophylactic vaccination in human to end this global pandemic. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused more than 209 million people infections and 4.4 million deaths as of Aug 21, 2021; while the global pandemic of COVID-19 has provided a large number of opportunities for mutation. Especially, the circulating variants of SARS-CoV-2 of Delta resulted in accelerated worldwide spreading of the virus. Various studies showed that the Delta variant is more infectious and dangerous, reducing the immune efficacy and protection of existing vaccines, inducing immune escape and leading to re-infection in people who have recovered from the wild-type SARS-CoV-2 1,2 . Currently, there are nearly 100 vaccines in clinical trials and 200 pre-clinical vaccine candidates [3] [4] [5] , however, few of these have shown significant protective efficacy against both SARS-CoV-2 and its circulating variants in the long term, the Delta variant in particular 1,6 . Therefore, an effective vaccine against wild-type SARS-CoV-2 and its variants is urgent in demand. Adeno-Associated Virus (AAV) has been widely used for gene therapy due to its safety and long-term characteristics, with high efficacy and low immunogenicity 7-9 , which highly addressed the requirements of ideal vaccine vectors. The prevalence of pre-existing NAs (PNAs) against AAV vectors is directly related to vaccine efficacy 10 ; while AAV type 5 (AAV5) with low PNAs (3.2%) 11, 12 and high affinity to human airway epithelia 13 possesses a great potential to be developed as the most optimal vaccine vector. Moreover, the safety of AAV5 vector in human has been well studied and evaluated 14 . Although currently recombinant engineering AAV vector has been used for effective gene delivery 15, 16 , whether it is compatible to human still requires clinical trial to prove. Therefore, we utilized AAV5 delivery vehicle to produce a broad and long-term protective vaccine against SARS-CoV-2 and its variants. In order to systematically screen the most effective SARS-CoV-2 spike (S) protein antigen for inducing immune response, we first designed five single-stranded DNA recombinant AAV5-based (ssAAV5) vaccines: ssAAV5-RBD (encodes the residues 319-541 RBD of S protein), ssAAV5-RBD-plus (encodes the residues 331-583 RBD-plus of S protein), ssAAV5-S1 (encodes the residues 14-685 of S1), ssAAV5-S (encodes the residues 14-1213 of extracellular domain of S protein), and ssAAV5-NTD (encodes the residues 14-305 of NTD) (Fig.1A) and continued until day 130 after single dose immunization (Fig.1C ). Among these groups, ssAAV5-RBD-plus elicited the highest specific IgG and NA titers, which indicates that RBD-plus domain with residues 331-583 was able to elicit the strongest immune response against wild-type SARS-CoV-2 in comparison with other antigens. Meanwhile, T-cell responses after vaccination were evaluated. After 130 days of ssAAV5-RBD-plus vaccine immunization, populations of the memory CD4 + and CD8 + T cells were found to be significantly increased ( Fig. 2A and 2B) along with significant upregulation of cytokine IFN-γ secretion from CD8 + compared to the controlled animals (Fig. 2C) . These results indicate that ssAAV5-based RBD-plus vaccine could effectively induce both robust systemic humoral and cell-mediated immune responses. Effective optimal dosage is a critical factor for a vaccine. To find out the optimal dosages of ssAAV5-RBD-plus vaccine, we first vaccinated mice by i.m at dosages of 1×10 8 , 1×10 9 , 1×10 10 , and 1×10 11 GCs, respectively. The results showed that the titers of IgG and NA were elevated with increasing of dosages while the animals vaccinated with 1×10 11 GCs showed the strongest immunogenicity ( Fig. 2D and 2E ). To further clarify whether 1×10 11 GCs was the most effective dosage, higher dosages with 2×10 11 and 4×10 11 GCs were vaccinated to mice. As shown in Fig. 2F and 2G, animals vaccinated with 1×10 11 GCs obtained the strongest immune responses. Based on these results, 1×10 11 GCs in the ssAAV5-based vaccine were determined as the optimal dose for further studies. Then, SARS-CoV-2 virus challenge test was applied to determine the protective effect of ssAAV5-RBD-plus vaccine on 6-week old (Young) and 36-week old (Old) BALB/c mice by a single dose of 6×10 10 Compared to ssAAV5-based vaccine, scAAV5-based vaccine elicited higher titers of specific IgG and NA, which indicates that scAAV5-based vaccine was able to elicit a stronger immune response against SARS-CoV-2. To verify the optimal dosages of scAAV-RBD-plus vaccine, we then vaccinated mice by i.m at dosages of 1×10 9 , 5×10 9 , 1×10 10 and 1×10 11 GCs, respectively. The results showed that the titers of IgG and NA were elevated with increasing of dosages while the animals vaccinated with 1×10 11 GCs showed the strongest immunogenicity ( Fig. 5E and 5F ). To further corroborate our findings, we tested the immune antigenicity of scAAV-RBD-plus vaccine in Wistar rats. The sera of the vaccinated rats were collected on days 40, 70, 100, 130, 220 and 334 after vaccine inoculation to evaluate the influences of humoral immunity and the level of NA. Results showed that scAAV vaccine was able to continuously induce production of IgG and the wild-type virus-specific NA during the 334-day experiment ( Fig. 6A and 6B ). After that, the sera from all vaccinated rats on day 334 were collected and the NA titers against SARS-CoV-2 variants were determined. Similar to the effect on wild-type virus, a single dose of scAAV-RBD-plus vaccine exhibited high level of serum NAs against the major current circulating variants: Alpha, Beta, Gamma and Delta variants (Fig. 6C ). During the entire experimental processes, all the vaccinated rats showed no adverse responses along with continued increase in body weight (Fig.6D) . These results indicated that the scAAV5-based RBD-plus vaccine (Covaccinplus) could provide a broad and long-term immune protection against SARS-CoV-2, especially for the major circulating variants such as Delta. In summary, both the single-stranded and the self-complementary rAAV5-based RBD-plus vaccines (Covaccinplus) represent safe and promising candidates for preventive intervention against SARS-COV-2; while our newly established recombinant rAAV5-delivery vehicle would provide a novel platform for the rational design of several new recombinant virus vector-based vaccines. These vaccines in the current study possess three unique advantages to combat the pandemic. Firstly, it induces strong and long-term immunogenicity and maintains high titers of NAs with live wide-type SARS-CoV-2 even after one year vaccination, without the need of a booster dose after primary vaccination in contrast to other vaccines 1, 18 . This RBD-plus vaccine also exhibited high level of long-lasting NAs with a range of 1:500-1:1024 responding to live SARS-CoV-2 variants including Alpha, Beta and Gamma, at the optimal dosage with 1x10 11 GCs, especially to Delta variant which is markedly resistant to the currently available vaccines. Therefore, the rAAV-based vaccine represents a powerful candidate to battle the COVID-19 pandemic 15 . Secondly, as a non-pathogenic and non-enveloped virus, rAAV5 vector is a safe and highly efficient vaccine delivery vehicle. In over one year experiment, none of the vaccinated animals developed adverse effects. We further determined the whole genome sequencing of tissues from one-year vaccinated mice, vector DNA sequences were not detected. Thirdly, rAAV vaccines have been reported to be very stable at -20 degree Celsius or even under room temperature 15 . This indicates that it will be very convenient for storage and transportation, which will largely contribute to the commercialization of the vaccine. Taken together, rAAV5-based RBD-plus vaccine (Covaccinplus) is a very promising candidate vaccine to end this global pandemic. The recombinant type 5 adenoviral-vectored SARS-CoV-2 vaccines encoding RBD domain (residues 319-541), RBD-plus domain (residues 319-583), S1 protein, full-length of S protein and NTD domain of SARS-CoV-2 were produced by PackGene Biotech (Guangzhou, China). Briefly, rAAV5 packaging plasmids were transfected into HEK293T cells using PEI transfection reagent, according to the manufacturer's protocol. The transfected cells and supernatants were harvested 72 h post transfection. rAAV5-vaccine was purified and titrated by real-time quantitative PCR (Q-PCR). rAAV5-vaccine was adjusted to 10 12 GCs/ml in PBS and used for the following vaccinations. Specific IgG and IgM against COVID-19 in mouse sera were tested by ELISA. Briefly, serially diluted mouse sera were added to 96-well microtiter plates pre-coated with RBD-His or S1-His protein. The plates were incubated at 37 for 30 min, Single-cell suspensions (3x10 6 ) from spleens of the vaccinated mice were harvested and stimulated with or without SARS-CoV-2 S-specific peptide (1μg/ml) plus anti-mouse IL-2 (20 U/ml). Cells with stimulatory agents were incubated for 72 hour at 37 with 5% CO 2 . The cells were harvested and stained directly with conjugated mAbs specific for cell surface markers including CD45， CD3， CD4， CD8， CD44，CD62L for 30 min at 4℃. Intracellular antigens including IFN-γ, IL-4 and TNF-α were stained for 20 minutes in the dark at room temperature. The stained cells were analyzed using a flow cytometer (BD company). Data were analyzed by Cell Quest software (company). Values were presented as mean with SEM. Statistical significance among different vaccination groups was calculated by the student t test using Stata statistical software (GraphPad Prism 7). Values of P<0.05 were considered significant. the Science Research Project of the Guangdong Province 2020A1111340003) and China Postdoctoral Science Foundation (Grant No China) provided RBD-plus vaccines for the studies. The PackGene Biotech Co., Ltd. (Guangzhou，China) provided supports in production of RBD-plus vaccines. The GMP level plasmids were produced by Yaohai Bioharmaceutical Co., Ltd Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand? SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants Adeno-associated virus vector as a platform for gene therapy delivery Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer Prevalence of Serum IgG and neutralizing factors against Adeno-Associated Virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: Implications for gene therapy using AAV vectors Immunogenicity of an AAV-based, room-temperature stable, single dose COVID-19 vaccine in mice and non-human primates. bioRxiv : the preprint server for biology A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile Neutralizing antibodies against SARS-CoV-2 variants after infection and vaccination Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection Broad neutralization of SARS-related viruses by human monoclonal antibodies SARS-CoV-2 spike E484K mutation reduces antibody neutralisation Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers This study was partially funded by Guangzhou Laboratory (Grant No. 2 Harbin Veterinary Research Institute，Harbin, China. Liang Liu, Chinyu Li and Guochao Liao are the cofounders of the Guangdong Hengda Biomedical Technology Co., Ltd., Guangzhou, China.